Search Results
Jun 07, 2026, 20:10 ET Ascletis Reinforces Its Differentiated Obesity Portfolio at American Diabetes Association (ADA) 2026 Scientific Sessions, Showcasing ASC30 Clinical Data and Exciting Preclinical Findings from ASC37 and ASC39
showed dose-proportional pharmacokinetics across the 2 mg to 60 mg dose range, with a peak-to-trough ratio of below 2:1. In a 4-week Phase I study, ASC30 demonstrated favorable safety and tolerability across all doses (20 mg, 40 mg, and 60 mg), with no hepatic safety signals or elevations in alanine
More news about: Ascletis Pharma Inc.
Jun 07, 2026, 20:10 ET 歌禮ASC30臨床數據與ASC37、ASC39令人振奮的臨床前結果於美國糖尿病協會（ADA）2026年度科學會議齊亮相，夯實差異化肥胖管線
如噁心和過度食慾抑制。在一項飲食誘導肥胖（DIO）大鼠模型中，ASC39以0.2 mg/kg、1 mg/kg和5 mg/kg的劑量每日一次口服給藥。研究觀察到體重下降呈明顯的劑量依賴性（dose-dependent）。在第11天時，接受5 mg/kg ASC39治療的動物體重較基線下降了9.9%，而安慰劑組的下降了2.8%（p < 0.01）。在另一項頭對頭DIO大鼠研究中，將ASC39（5 mg/kg，口服，每日一次）與eloralintide（3 nmol/kg，皮下注射，每三天一次）進行了比較。開始給藥後的第2天，兩種藥物均開始引起體重下降。到第7天時，ASC39組和eloralintide組的體重較基線分別下降了6.0%（p
More news about: 歌禮製藥有限公司
Jun 07, 2026, 17:30 ET Novo Nordisk's CagriSema 2.4 mg / 2.4 mg demonstrated significant reduction in HbA1c and weight across multiple studies in the REIMAGINE program presented at ADA 2026
CagriSema 2.4 mg/2.4 mg and 1 mg/1 mg once-weekly versus placebo in 189 adults with type 2 diabetes inadequately controlled on diet and exercise. REIMAGINE 2 was a 68-week efficacy and safety phase 3 trial of CagriSema 2.4 mg/2.4 mg and 1 mg/1 mg once-weekly versus semaglutide 2.4 mg, semaglutide 1 mg, cagrilintide
More news about: NOVO NORDISK INC.
Jun 07, 2026, 16:45 ET Lipid-Lowering Medications Demonstrate Cardiometabolic Benefits in Populations with High-Risk Diabetes
were similar in patients with diabetes (median 784 mg/dL) compared to those without diabetes (807 mg/dL; p=0.43), but those with diabetes history were more likely to have had prior AP (21% vs. 14%; p=0.005). Compared with placebo, the 50 mg and 80 mg doses of olezarsen reduced TGs by 57.4% (95% CI 48.6-66.2)
More news about: American Diabetes Association
Jun 07, 2026, 16:45 ET AMGEN PRESENTS NEW DATA ACROSS ITS CARDIOMETABOLIC PORTFOLIO AT AMERICAN DIABETES ASSOCIATION 86TH SCIENTIFIC SESSIONS
attack or stroke, an LDL-C ≥ 90 mg/dL, or non-high-density lipoprotein cholesterol (non-HDL-C) ≥ 120 mg/dL, or apolipoprotein B ≥ 80 mg/dL; and treated with highest tolerated dose of statin and/or ezetimibe. The median baseline LDL-C was 122 mg/dL (IQR, 104-149 mg/dL) on local lab testing. Participants
More news about: Amgen
Jun 07, 2026, 14:30 ET Head-to-head Study Validates the Clinical Advantage of New-generation Biased GLP-1: Ecnoglutide Delivers 35% Greater Weight Loss than Semaglutide
Participants were randomized 1:1 to receive once-weekly subcutaneous injections of either ecnoglutide or semaglutide at the same maintenance dose of 2.4 mg¹.Study data showed that at week 20, the least-squares mean percentage change in body weight from baseline was -12.8% in the ecnoglutide group and
More news about: Sciwind Biosciences Co., Ltd.
Jun 07, 2026, 11:00 ET Lilly's Foundayo (orforglipron), the only oral GLP-1 taken without food or water restrictions, was associated with significant weight loss in women at every stage of menopause
Foundayo 0.8 mg once-daily and then increased the dose in a step-wise approach at four-week intervals to their final randomized maintenance dose of 5.5 mg (via steps at 0.8 mg and 2.5 mg), 9 mg (via steps at 0.8 mg, 2.5 mg and 5.5 mg) or 17.2 mg (via steps at 0.8 mg, 2.5 mg, 5.5 mg, 9 mg and 14.5 mg). These
More news about: Eli Lilly and Company
Jun 07, 2026, 08:00 ET Wegovy® pill prescriptions surpass 3 million, 1 filled roughly every 5 seconds, bringing GLP-1 therapy to people with obesity previously untreated, while Novo Nordisk unveils new data at ADA 2026
Denmark, June 7, 2026 /PRNewswire/ -- Novo Nordisk today announced Wegovy® (semaglutide) tablets 25 mg has surpassed three million prescriptions in just over five months, establishing Wegovy® pill as one of the strongest US pharmaceutical launches
More news about: NOVO NORDISK INC.
Jun 06, 2026, 14:45 ET 82% of Adults with Type 2 Diabetes Not on Insulin Improve Blood Glucose Levels with Continuous Glucose Monitoring
0.9% greater A1C reduction after six months in the CGM group compared with the Routine Care control group. Time in the glucose target range of 70 to 180 mg/dL was a remarkable five hours per day greater with CGM than with routine care. Participants in the CGM group expressed greater satisfaction with glucose
More news about: American Diabetes Association
Jun 06, 2026, 14:30 ET Lilly's triple agonist, retatrutide, drove substantial improvements in weight, A1C, knee osteoarthritis pain, and obstructive sleep apnea, demonstrating its remarkable potential to treat obesity and its complications
retatrutide initiated treatment with 2 mg once-weekly and increased the dose in a step-wise approach every four weeks until reaching the target dose of 4 mg (via one step at 2 mg), 9 mg (via steps at 2 mg, 4 mg and 6 mg) or 12 mg (via steps at 2 mg, 4 mg, 6 mg and 9 mg).The TRANSCEND-T2D Phase 3 clinical
More news about: Eli Lilly and Company
Jun 06, 2026, 14:30 ET Breakthrough Studies Demonstrate Effectiveness of the First Triple-Hormone Therapy for Type 2 Diabetes and Obesity
receive a once-weekly injection of 4, 9, and 12 mg retatrutide, or placebo for 80 weeks.For the primary endpoint, participants taking retatrutide 9 mg and 12 mg lost an average of 64.4 lbs (25.9%) and 70.3 lbs (28.3%), respectively. Those taking the 4 mg dose of retatrutide, with just a single dose
More news about: American Diabetes Association
Jun 06, 2026, 13:00 ET Novo Nordisk to present new data on Wegovy® across a wide range of cardiometabolic conditions at the American Diabetes Association's 2026 Scientific Sessions
the goal of going beyond weight loss to improvements in overall health."It is important to note that semaglutide injection 2.4 mg and semaglutide tablets 25 mg contain a Boxed Warning for possible thyroid tumors, including cancer, and should not be used in those with a personal or family history
More news about: NOVO NORDISK INC.
Jun 06, 2026, 09:07 ET People with type 2 diabetes who were increased to semaglutide 2 mg were as likely to achieve an HbA1c less than 7% and more likely to achieve greater than 5% weight loss than those who were switched to tirzepatide, in real-world data
type 2 diabetes on semaglutide 1 mg whose dose was increased to 2 mg were as likely to reach an HbA1c level <7% and were more likely to see weight loss of ≥5% vs those who were switched to tirzepatide 2.5 mg or 5 mg with allowed titration up to 15 mg1 This retrospective
More news about: Novo Nordisk
Jun 06, 2026, 09:01 ET People with type 2 diabetes who were increased to semaglutide 2 mg were as likely to achieve an HbA1c less than 7% and more likely to achieve greater than 5% weight loss than those who were switched to tirzepatide, in real-world data
type 2 diabetes on semaglutide 1 mg whose dose was increased to 2 mg were as likely to reach an HbA1c level <7% and were more likely to see weight loss of ≥5% vs those who were switched to tirzepatide 2.5 mg or 5 mg with allowed titration up to 15 mg1 This retrospective
More news about: Novo Nordisk
Jun 06, 2026, 09:00 ET Ultra-Long-Acting Injectable GLP-1 RA Shows Promise for Supporting Weight Management in Individuals With and Without Type 2 Diabetes
individuals living with overweight or obesity. After 28 weeks of treatment, berobenatide demonstrated placebo-adjusted weight loss of up to 12.3% with the 4.8 mg monthly dose. The safety and tolerability was consistent with the GLP-1 RA class."Berobenatide is a potentially important new option
More news about: American Diabetes Association
Jun 05, 2026, 19:33 ET Ambrosia Biosciences Announces Preclinical Data Supporting Differentiated Profile of AMB-702, its Novel Small Molecule GLP-1 Receptor Agonist Development Candidate
non-human primate (NHP) model. In a head-to-head comparison, AMB-702 achieved placebo-adjusted mean weight loss of 12.6% after 7 days of daily dosing at 2 mg/kg, compared to 5.4% for orforglipron at the same dose and formulation. AMB-702 also demonstrated improved glycemic control and enhanced insulin secretion
More news about: Ambrosia Biosciences
Jun 05, 2026, 19:30 ET Novo Nordisk's investigational zenagamtide shows significant A1C reductions with up to 14.6% weight loss in adults with type 2 diabetes--presented at ADA 2026
for a short period of time (ie 20 mg for 8 weeks and 40 mg for 4 weeks).1As a key supportive secondary endpoint, trial participants taking zenagamtide also saw a mean body weight reduction of up to 14.6% (baseline body weight ~219 lbs) with the 40 mg dose compared with 2.1% with placebo.1
More news about: NOVO NORDISK INC.
Jun 05, 2026, 18:30 ET First Dual GLP-1/GIP Receptor Agonist Developed for Type 1 Diabetes Shows Promising Benefits in Blood Glucose Control
obesity (body mass index (BMI) greater than or equal to 27 kg/m²). Participants were randomly assigned to receive acmopatide at doses of 1.8 mg, 4.1 mg, 6.6 mg, or placebo. The study's primary endpoint was change in A1C, a measure of average blood glucose levels over the previous 2 to 3 months, from baseline
More news about: American Diabetes Association
Jun 05, 2026, 10:23 ET Update zu innovativem Arzneimittel | Kexing Biopharm nimmt ersten Studienteilnehmer in die in China durchgeführte klinische Phase-I-Studie mit dem innovativen ophthalmologischen Arzneimittel GB10 auf
eigenständig entwickelt wurde. Sie enthält einen bispezifischen Antikörper, der gegen VEGF und Ang-2 gerichtet ist. Mit einer hohen Konzentration von 140 mg/ml ermöglicht GB10 Injection ein geringeres Injektionsvolumen oder eine höhere Dosierung und verlängert dadurch das Verabreichungsintervall. Es wird
More news about: Kexing Biopharm
Jun 05, 2026, 09:00 ET VetrixBio Announces Positive Clinical Data for VTX-304, a First-in-Class Bispecific Antibody for Canine Osteoarthritis
Key findings presented:In a natural OA model with aged Beagles (mean age 10.8 years), VTX-304 (dosed at 2.5 mg/kg SC) delivered pain relief comparable to the anti-NGF monoclonal antibody bedinvetmab, as measured by the modified Canine Brief Pain Inventory (mCBPI).In
More news about: VetrixBio, Inc.
Jun 05, 2026, 06:16 ET Actualización sobre fármacos innovadores | Kexing Biopharm inscribe al primer sujeto en el ensayo clínico de fase I en China del fármaco oftálmico innovador GB10
biespecífico que se dirige tanto al factor de crecimiento endotelial vascular (FCEV) como a la angiopoyetina-2 (Ang-2). Con una alta concentración de 140 mg/ml, el GB10 inyectable permite un menor volumen de inyección o una dosis más alta, lo que prolonga el intervalo entre dosis. Se espera que permita un régimen
More news about: Kexing Biopharm
Jun 05, 2026, 06:13 ET Atualização sobre medicamentos inovadores | Kexing Biopharm recruta o primeiro participante para o ensaio clínico de Fase I do medicamento oftalmológico inovador GB10, realizado na China
independente pela Shenzhen Kexing. Ele contém um anticorpo biespecífico que tem como alvo ambas as proteínas VEGF e Ang-2. Com uma alta concentração de 140 mg/mL, a injeção de GB10 permite um volume de injeção menor ou uma dosagem mais elevada, aumentando assim o intervalo entre as doses. O objetivo é alcançar
More news about: Kexing Biopharm
Jun 05, 2026, 06:03 ET Sungrow Expands Residential ESS Portfolio with Next-Gen Solution for Reliable Backup Power
provider, unveiled its next-generation residential energy storage solution, expanding its power range from 5 kW to 12 kW with the introduction of the new MG12RL hybrid inverter.
More news about: Sungrow
Jun 05, 2026, 06:02 ET 13 Top Press Releases from May
Lilly's triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trialIn TRIUMPH-1, participants on 12 mg retatrutide lost an average of 70.3 lbs (28.3%) over 80 weeks with 45.3% of participants achieving ≥30% weight loss, a level long associated with bariatric
More news about: PR Newswire
Jun 05, 2026, 06:00 ET Nieuws over innovatieve geneesmiddelen | Kexing Biopharm neemt eerste proefpersoon op in de in China uitgevoerde fase I-klinische studie naar het innovatieve oogheelkundige geneesmiddel GB10
Kexing zelfstandig is ontwikkeld. Het bevat een bispecifiek antilichaam dat zich zowel op VEGF als op Ang-2 richt. Dankzij de hoge concentratie van 140 mg/ml maakt GB10 Injectie een kleiner injectievolume of een hogere dosering mogelijk, waardoor het doseringsinterval kan worden verlengd. Naar verwachting
More news about: Kexing Biopharm